Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Axonics Modulation Technologies Inc Market Cap
Based on ratings from 5 stock analysts, the Axonics Modulation Technologies Inc stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Axonics Modulation Technologies Inc. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
AXNX is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Wells Fargo and on the lower end AXNX is forecasted to be $ by from Wells Fargo.
These are the latest 20 analyst ratings of AXNX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mike Matson Needham | Hold | Reiterates | Nov 8, 2024 | |
| Mike Matson Needham | Hold | Reiterates | Aug 5, 2024 | |
| Mike Matson Needham | Hold | Reiterates | May 6, 2024 | |
| Shagun Singh RBC Capital | Sector Perform | $71 | Reiterates | Feb 29, 2024 |
| Mike Matson Needham | Hold | Downgrade | Jan 17, 2024 | |
| David Rescott Truist Securities | Hold | $71 | Downgrade | Jan 16, 2024 |
| David Rescott Truist Securities | Hold | $71 | Downgrade | Jan 12, 2024 |
| Adam Maeder Piper Sandler | Neutral | $71 | Downgrade | Jan 12, 2024 |
| Kristen Stewart CL King | Neutral | Downgrade | Jan 12, 2024 | |
| Mike Kratky Leerink Partners | Market Perform | $71 | Downgrade | Jan 12, 2024 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $71 | Downgrade | Jan 10, 2024 |
| Mike Polark Wolfe Research | Peer Perform | Downgrade | Jan 9, 2024 | |
| David Rescott Truist Securities | Buy | $73 | Maintains | Dec 22, 2023 |
| Adam Maeder Piper Sandler | Overweight | $75 | Maintains | Oct 31, 2023 |
| Mike Matson Needham | Buy | $63 | Maintains | Oct 31, 2023 |
| Cecilia Furlong Morgan Stanley | Overweight | $69 | Maintains | Oct 31, 2023 |
| Mike Kratky Leerink Partners | Outperform | $70 | Initiates | Oct 16, 2023 |
| David Rescott Baird | Outperform | $70 | Maintains | Jul 28, 2023 |
| Matthew Mishan Keybanc | Overweight | $71 | Maintains | Jul 28, 2023 |
| Mike Matson Needham | Buy | $76 | Maintains | Jul 28, 2023 |
When did it IPO
2018
Staff Count
797
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Raymond W. Cohen
Market Cap
$3.63B
In 2023, AXNX generated $366.4M in revenue, which was a increase of 33.86% from the previous year. This can be seen as a signal that AXNX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Boston Scientific Corporation has completed its acquisition of Axonics, Inc., enhancing its portfolio in medical technology for urinary and bowel dysfunction treatment.
Why It Matters - The acquisition enhances Boston Scientific's product portfolio and market position in medical devices, potentially driving revenue growth and investor confidence.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Axonics, Inc. reported Q3 2024 revenue growth of 25% year over year, reflecting strong performance in its minimally invasive products for bladder and bowel dysfunction.
Why It Matters - Axonics’ 25% revenue growth signals strong demand for its products, indicating effective business execution and potential for future profitability, impacting investor sentiment positively.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Axonics Modulation Technologies (AXNX) reported Q3 earnings of $0.16 per share, surpassing estimates of $0.13 and up from $0.08 per share year-over-year.
Why It Matters - Axonics’ earnings beat estimates and show significant year-over-year growth, indicating strong performance and potential for future profitability, which could drive investor confidence and stock price.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - AXNX's R20 rechargeable SNM system, designed for bladder and bowel dysfunction, has received approval in Australia.
Why It Matters - AXNX's R20 approval in Australia can boost revenue prospects, enhance market position, and signal potential for further international expansion, impacting stock performance positively.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Axonics, Inc. has received TGA approval to market its Axonics R20® rechargeable sacral neuromodulation system in Australia for treating overactive bladder and fecal incontinence.
Why It Matters - Axonics' TGA approval for the R20 system opens a new market in Australia, enhancing growth prospects and potential revenue, which can positively impact stock performance.
Wed, 25 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AXNX stock rises after a favorable court ruling in patent litigation against Medtronic.
Why It Matters - AXNX's stock surge indicates investor confidence in its competitive position and potential revenue growth, positively impacting future valuations and market sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
